Drug Delivery Company has filed a notice of an exempt offering of securities to raise $1,500,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Drug Delivery Company is raising $1,500,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jeffrey Benner played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Drug Delivery Company
We are a research and development firm focusing on bringing forward a medication for opioid use disorder. Our firm is developing a sustained-release, subcutaneous naltrexone implant that will deliver the drug for at least six months. Once approved, this will be the first new treatment for opioid use disorder to come on the market since 2006. Pre-clinical studies have shown that our product is safe and effective. Phase 1 human clinical studies are projected to begin in Q2 2023.
To learn more about Drug Delivery Company, visit http://akysomed.com/
Contact:
Jeffrey Benner, Chief Executive Officer
410-546-8037
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.